#DynamX® bioadaptor and INFINITY-SWEDEHEART 12-month data are among the top highlights from Dr. Mirvat Alasnag and Dr. Khaled Shaibi’s review of Day 4 highlights from the #ESCongress. Watch the full video here: https://lnkd.in/e-VNwCqw CE marked. Not for sale in the U.S. #Cardiovascular #Medtech #Innovation #leavetherightthingbehind PMN 2009 Rev A
Elixir Medical Corporation
Medical Device
Milpitas, CA 6,073 followers
Elixir Medical is committed to transforming care for patients with heart and vascular disease through innovation.
About us
Elixir Medical is committed to transforming care of patients with heart and vascular disease through innovation. Since 2005, the company has continually sought to improve the treatment of vascular disease with: - Drug-eluting coronary stent systems (DES) - Fully resorbable drug-eluting scaffold systems (BRS) - Drug-eluting coronary bioadaptor systems Its latest innovation — the DynamX™ Coronary Bioadaptor System — is designed to be a significant advancement beyond drug-eluting stents (DES). Elixir Medical’s innovations are designed to make a meaningful change in patients’ lives. The company does not simply want to engineer a better medical device. Saving lives and helping patients enjoy their daily life is what drives us every day.
- Website
-
http://www.elixirmedical.com
External link for Elixir Medical Corporation
- Industry
- Medical Device
- Company size
- 51-200 employees
- Headquarters
- Milpitas, CA
- Type
- Privately Held
- Founded
- 2005
- Specialties
- Cardiac and Vascular Interventional Medical Devices
Locations
-
Primary
920 N. McCarthy Blvd.
Suite 100
Milpitas, CA 95035, US
-
IDA Business and Technology Park
Carrick-on-Shannon, Co. Leitrim, IE
Employees at Elixir Medical Corporation
Updates
-
Join our discussion, hosted by incathlab, on percutaneous coronary intervention (PCI) outcomes on September 18! 1-year outcomes from INFINITY-SWEDEHEART RCT recently presented at #ESCCongress demonstrated that #DynamX® Bioadaptor meets primary endpoint and significantly reduces adverse events compared to DES after 6 months.¹ Davide Capodanno, Rasha Al-Lamee, Santoso Teguh, David Erlinge, and Johan Bennett will focus on how #DynamX® bioadaptor can help improve patients' clinical outcomes in real life. Add to calendar and register here: https://lnkd.in/ekuteewE CE marked. Not for sale in the U.S. ¹ D. Erlinge INFINITY-SWEDEHEART 1-year outcomes. ESC 2024 #MedTech #Innovation PMN 2007 Rev A
-
-
Elixir Medical Corporation reposted this
Congratulations to the team at Elixir for the excellent results from Infinity-Swedeheart trial for meeting its primary end point Fantastic reduction of TLF in 12 months This was announced at ESC on Monday 1pm London time In Malaysia it was my regular cath day where we implanted another DynamX Bioadaptor just before the ESC announcement This gentleman presented with symptoms of angina We treated the Mid LAD with the Bioadaptor while the distal was treated with a drug coated balloon PCI was OCT guided Hope this patient can benefit from this hybrid approach using this latest innovation #elixir #dynamX #bioadaptor #angioplasty #medtronic #prevail #dcb #cardiology #hearthealth #ijn
-
-
🚨 NEW DATA: INFINITY-SWEDEHEART RCT 12-month outcomes comparing #DynamX® with a contemporary DES ➡️ The study met its primary endpoint of target lesion failure (TLF) non-inferiority. ➡️ Landmark analysis (6-12 months) showed DynamX bioadaptor significantly reduces adverse events compared to DES, confirming unique mechanism of action after unlocking at 6 months. Learn more about the results: https://lnkd.in/epNfckFD CE marked. Not for sale in the U.S. #ESC2024 #Cardiovascular #Medtech #Innovation #leavetherightthingbehind PMN 2002 REV A
-
📣 Attending #ESCongress? We’re looking forward to presenting one-year primary outcomes from the INFINITY-SWEDEHEART randomized clinical trial (RCT) comparing #DynamX® with the contemporary Resolute Onyx™ zotarolimus drug-eluting stent (DES). Join us during HOT LINE session #11 on Monday, September 2, 2024 at 13:45 BST. David Erlinge Stefan James CE marked. Not for sale in the U.S. #Cardiovascular #Medtech #Innovation #leavetherightthingbehind PMN 2000 Rev A
-
-
Congratulations to Dr. Julia Mascherbauer, Dr. Paul Vock and the team at St. Pölten University on your first #DynamX implant in the BIO-RESTORE post-market registry. The team treated a 67-year-old patient with a tortuous proximal right coronary artery (RCA). Thank you to our local, exclusive Austrian partner, NOVOMED Handels-GesmbH, for supporting the case. #Innovation #Cardiology #leavetherightthingbehind #bioadaptor CE marked. Not for sale in the U.S. PMN 1992 Rev A
-
-
Elixir Medical Corporation reposted this
Professor Titular da Disciplina de Cardiologia da Faculdade de Medicina USP e Diretor de Hemodinâmica e Cardiologia Intervencionista no Instituto do Coração - InCor HCFMUSP
DESyne BDS Plus Trial: FIM Outcomes of Triple-Drug Antithrombotic DES Discussing the findings and implications of DESyne BDS Plus study. The conversation delves into the study's design, key results at 12-month follow-up and future potential impact on clinical practice. Balancing ischaemic and bleeding risk with oral anti-thrombotic drugs remains a significant clinical challenge, especially in patients who are at high thrombotic risk and high bleeding risk. 12-month results from DESyne BDS Plus RCT demonstrate the safety and effectiveness of site specific anti-thrombotic drug therapy (TRx) with significantly lower TLF rate (2.1% vs. 9.3%, p=0.030) vs the contemporary DES group in complex patients.1 The interview highlights how the RCT findings could potentially impact patient outcomes post-intervention and influence clinical practice. Discutindo os achados e as implicações do estudo DESyne BDS Plus. A conversa explora o desenho do estudo, os principais resultados no seguimento de 12 meses e o potencial impacto futuro na prática clínica. Equilibrar o risco isquêmico e o risco de sangramento com medicamentos antitrombóticos orais continua sendo um desafio clínico significativo, especialmente em pacientes com alto risco trombótico e alto risco de sangramento. Os resultados de 12 meses do RCT DESyne BDS Plus demonstram a segurança e a eficácia da terapia antitrombótica específica para o local (TRx) com uma taxa de TLF significativamente menor (2,1% vs. 9,3%, p=0,030) em comparação ao grupo contemporâneo de DES em pacientes complexos. A entrevista destaca como os achados do RCT podem potencialmente impactar os desfechos dos pacientes após a intervenção e influenciar a prática clínica.
DESyne BDS Plus Trial: FIM Outcomes of Triple-Drug Antithrombotic DES
radcliffecardiology.com
-
Watch Dr. Mirvat Alasnag as she offers her perspective on the BIOADAPTOR RCT two-year data and the impact the results could have on her practice and the future of PCI. #Innovation #Cardiology #Bioadaptor CE marked. Not for sale in the U.S. PMN 1994 REV A
📹 Stream an exclusive interview with Dr Mirvat Alasnag on the #BioadaptorRCT trial two-year findings! 🔗 https://ow.ly/BAEM50T1ccz Discover how these groundbreaking results could shape the future of #PCI. Explore the study’s design, key findings and implications for clinical practice 🥼🔬 #Cardiology
-
-
💡 Hear from Dr. Santoso Teguh as he shares his experience with the #DynamX bioadaptor and his observations on the impact it has on patient outcomes in his practice. View the full video here: https://lnkd.in/eWJnqqrj CE marked. Not for sale in the U.S. #Cardiovascular #Medtech #Innovation #leavetherightthingbehind PMN 1946 Rev A
-
We are very excited to share that Curaçao Medical Center (CMC) now offers bioadaptive angioplasty with the DynamX bioadaptor, a revolutionary innovation in percutaneous coronary intervention (PCI), to patients in the Caribbean Islands. The DynamX bioadaptor has shown to restore artery motion and function resulting in hemodynamic modulation and improved health outcomes compared to drug-eluting stents.¹ ² Congratulations to the entire CMC Cathlab team, and in particular to Dr. Arthur Liqui Lung, Cardiology Medical Director, and Dr. Jose Torres and Dr. José Navarro. #DynamX ¹ Saito S. et al. 12-month clinical and imaging data from the multi-centre, international, BIOADAPTOR RCT. eClinicalMedicine Lancet. 2023 ² Presented by Shigeru Saito, MD, at EuroPCR 2024
-